A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax

Vaccine

Volumn 29, Issue 27, 2011, Pages 4521-4533

  Gorantala, Jyotsna ^a   Grover, Sonam ^a   Goel, Divya ^a   Rahi, Amit ^a   Jayadev Magani, Sri Krishna ^a   Chandra, Subhash ^a   Bhatnagar, Rakesh ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

Anthrax; Domain IV; Lethal toxin; Protection; Protective antigen; Transplastomic plants

Indexed keywords

ANTHRAX VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; PROTECTIVE ANTIGEN DOMAIN IV VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHLOROPLAST; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; IN VITRO STUDY; MACROPHAGE; MICROBIAL IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHIZOBIUM; SPORE GERMINATION; TH2 CELL; TRANSGENE; TREATMENT RESPONSE; VACCINE PRODUCTION; WESTERN BLOTTING;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CHLOROPLASTS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PLANTS, GENETICALLY MODIFIED; RHIZOBIUM; TOBACCO; TRANSFORMATION, GENETIC; VACCINATION; VACCINES, DNA;

EID: 79958112109     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.082     Document Type: Article

References (76)

1. Inglesby T.V., O'Toole T., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002, 287:2236-2252.
2. Manchee R.J., Stewart R. The decontamination of Gruinard Island. Chem Br 1988, 4:690-691.
3. Stuart A.L., Wilkening D.A. Degradation of biological weapons agents in the environment: implications for terrorism response. Environ Sci Technol 2005, 39:2736-2743.
4. Dixon T.C., Meselson M., Guillemin J., Hanna P.C. Anthrax. N Engl J Med 1999, 341:815-826.
5. Mock M., Fouet A. Anthrax. Annu Rev Microbiol 2001, 55:647-671.
6. Young J.A., Collier R.J. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu Rev Biochem 2007, 76:243-265.
7. Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R., Copeland T.D., et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998, 280:734-737.
8. Leppla S.H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci USA 1982, 79:3162-3166.
9. Friedlander A.M., Welkos S.L., Ivins B.E. Anthrax vaccines. Curr Top Microbiol Immunol 2002, 271:33-60.
10. Wang J.Y., Roehrl M.H. Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin. Med Immunol 2005, 4:4.
11. Ivins B.E., Pitt M.L., Fellows P.F., Farchaus J.W., Benner G.E., Waag D.M., et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 1998, 16:1141-1148.
12. Fellows P.F., Linscott M.K., Ivins B.E., Pitt M.L., Rossi C.A., Gibbs P.H., et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001, 19:3241-3247.
13. Pittman P.R, Gibbs P.H., Cannon T.L., Friedlander A.M. Anthrax vaccine: short-term safety experience in humans. Vaccine 2001, 20:972-978.
14. Levine M.M., Sztein M.B. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol 2004, 5:460-464.
15. Pitt .L., Little S., Ivins B.E., Fellows P., Boles J., Barth J., et al. In vitro correlate of immunity in an animal model of inhalational anthrax. J Appl Microbiol 1999, 87:304.
16. Williamson E.D., Hodgson I., Walker N.J., Topping A.W., Duchars M.G., Mott J.M., et al. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect Immun 2005, 73:5978-5987.
17. Mohamed N., Li J., Ferreira C.S., Little S.F., Friedlander A.M., Spitalny G.L., et al. Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect Immun 2004, 72:3276-3283.
18. Brahmbhatt T.N., Darnell S.C., Carvalho H.M., Sanz P., Kang T.J., Bull R.L., et al. Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen. Infect Immun 2007, 75:5240-5247.
19. Weiss M.M., Weiss P.D., Weiss J.B. Anthrax vaccine and public health policy. Am J Public Health 2007, 97:1945-1951.
20. Flick-Smith H.C., Walker N.J., Gibson P., Bullifent H., Hayward S., Miller J., et al. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect Immun 2002, 70:1653-1656.
21. Santelli E., Bankston L.A., Leppla S.H., Liddington R.C. Crystal structure of a complex between anthrax toxin and its host cell receptor. Nature 2004, 430:905-908.
22. Park Y.S., Lee J.H., Hung C.F., Wu T.C., Kim T.W. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect Immun 2008, 76:1952-1959.
23. Kaur M., Chug H., Singh H., Chandra S., Mishra M., Sharma M., et al. Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis. Mol Immunol 2009, 46:2107-2115.
24. Brossier F., Weber-Levy M., Mock M., Sirard J.C. Role of toxin functional domains in anthrax pathogenesis. Infect Immun 2000, 68:1781-1786.
25. McConnell M.J., Hanna P.C., Imperiale M.J. Adenovirus-based prime-boost immunization for rapid vaccination against anthrax. Mol Ther 2007, 15:203-210.
26. Fischer R., Stoger E., Schillberg S., Christou P., Twyman R.M. Plant-based production of biopharmaceuticals. Curr Opin Plant Biol 2004, 7:152-158.
27. Ma J.K., Barros E., Bock R., Christou P., Dale P.J., Dix P.J., et al. Molecular farming for new drugs and vaccines. Current perspectives on the production of pharmaceuticals in transgenic plants. EMBO Rep 2005, 6:593-599.
28. Kumar S., Daniell H. Engineering the chloroplast genome for hyperexpression of human therapeutic proteins and vaccine antigens. Methods Mol Biol 2004, 267:365-383.
29. De Cosa C.B., Moar W., Lee S.B., Miller M., Daniell H. Overexpression of the Bt cry2Aa2 operon in chloroplasts leads to formation of insecticidal crystals. Nat Biotechnol 2001, 19:71-74.
30. Chebolu S., Daniell H. Chloroplast-derived vaccine antigens and biopharmaceuticals: expression, folding, assembly and functionality. Curr Top Microbiol Immunol 2009, 332:33-54.
31. Limaye A., Koya V., Samsam M., Daniell H. Receptor-mediated oral delivery of a bioencapsulated green fluorescent protein expressed in transgenic chloroplasts into the mouse circulatory system. FASEB J 2006, 20:959-961.
32. Daniell H., Lee S.B., Panchal T., Wiebe P.O. Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts. J Mol Biol 2001, 311:1001-1009.
33. Tregoning J.S., Nixon P., Kuroda H., Svab Z., Clare S., Bowe F., et al. Expression of tetanus toxin fragment C in tobacco chloroplasts. Nucleic Acids Res 2003, 31:1174-1179.
34. Watson J., Koya V., Leppla S.H., Daniell H. Expression of Bacillus anthracis protective antigen in transgenic chloroplasts of tobacco, a non-food/feed crop. Vaccine 2004, 22:4374-4384.
35. Aziz M.A, Sikriwal D., Singh S., Jarugula S., Kumar P.A., Bhatnagar R. Transformation of an edible crop with the pagA gene of Bacillus anthracis. FASEB J 2005, 19:1501-1503.
36. Arlen P.A., Singleton M., Adamovicz J.J., Ding Y., Davoodi-Semiromi A., Daniell H. Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts. Infect Immun 2008, 76:3640-3650.
37. Molina A., Hervas-Stubbs S., Daniell H., Mingo-Castel A.M., Veramendi J. High-yield expression of a viral peptide animal vaccine in transgenic tobacco chloroplasts. Plant Biotechnol J 2004, 2:141-153.
38. Scotti N., Alagna F., Ferraiolo E., Formisano G., Sannino L., Buonaguro L., et al. High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts. Planta 2009, 229:1109-1122.
39. Davoodi-Semiromi A., Schreiber M., Nalapalli S., Verma D., Singh N.D., Banks R.K., et al. Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery. Plant Biotechnol J 2010, 8:223-242.
40. Aziz M.A., Singh S., Anand K.P., Bhatnagar R. Expression of protective antigen in transgenic plants: a step towards edible vaccine against anthrax. Biochem Biophys Res Commun 2002, 299:345-351.
41. Doyle J.J., Doyle J.L. Isolation of plant DNA from fresh tissue. Focus 1990, 12:13-15.
42. Kim H.U., Goepfert J.M. A sporulation medium for Bacillus anthracis. J Appl Microbiol 1974, 37:265-267.
43. Shoop W.L., Xiong Y., Wiltsie J., Woods A., Guo J., Pivnichny J.V., et al. Anthrax lethal factor inhibition. Proc Natl Acad Sci USA 2005, 102:7958-7963.
44. Kuroda H., Maliga P. Complementarity of the 16S rRNA penultimate stem with sequences downstream of the AUG destabilizes the plastid mRNAs. Nucleic Acids Res 2001, 29:970-975.
45. Williamson E.D., Beedham R.J., Bennett A.M., Perkins S.D., Miller J., Baillie L.W. Presentation of protective antigen to the mouse immune system: immune sequelae. J Appl Microbiol 1999, 87:315-317.
46. Koya V., Moayeri M., Leppla S.H., Daniell H. Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge. Infect Immun 2005, 73:8266-8274.
47. Aulinger B.A., Roehrl M.H., Mekalanos J.J., Collier R.J., Wang J.Y. Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines. Infect Immun 2005, 73:3408-3414.
48. Wright J.G., Quinn C.P., Shadomy S., Messonnier N. Centers for Disease Control and Prevention (CDC). Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2010, 59:1-30.
49. Shepard C.W., Soriano-Gabarro M., Zell E.R., Hayslett J., Lukacs S., Susan Goldstein, et al. Antimicrobial post-exposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 2002, 8:1124-1132.
50. Thomas J.M., Moen S.T., Gmade B.T., Vargas-Inchaustegui D.A., Foltz S.M., Saurez G., et al. Recombinant Sindbis virus vectors designed to express protective antigen of Bacillus anthracis protect animals from anthrax and display synergy with ciprofloxicin. Clin Vaccine Immunol 2009, 11:1696-1699.
51. Sussman H.E. Spinach makes a safer anthrax vaccine. Drug Discov Today 2003, 8:428-430.
52. Chichester J.A., Musiychuk K., de la Rosa P., Horsey A., Stevenson N., Ugulava N., et al. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 2007, 25:3111-3114.
53. Mantis N.J., Forbes S.J. Secretory IgA: arresting microbial pathogens at epithelial borders. Immunol Invest 2010, 39:383-406.
54. Zegers N.D., Kluter E., van Der S.H., van D.E., van D.P., Shaw M., et al. Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: towards the development of an oral vaccine against anthrax. J Appl Microbiol 1999, 87:309-314.
55. Gaur R., Gupta P.K., Banerjea A.C., Singh Y. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin. Vaccine 2002, 20:2836-2839.
56. Boyaka P.N., Tafaro A., Fischer R., Leppla S.H., Fujihashi K., McGhee J.R. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 2003, 170:5636-5643.
57. Matyas G.R., Friedlander A.M., Glenn G.M., Little S., Yu J., Alving C.R. Needle-free skin patch vaccination method for anthrax. Infect Immun 2004, 72:1181-1183.
58. Zeng M., Xu Q., Pichichero M.E. Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine. Vaccine 2007, 25:3588-3594.
59. Galen J.E., Zhao L., Chinchilla M., Wang J.Y., Pasetti M.F., Green J., et al. Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA. Infect Immun 2004, 72:7096-7106.
60. Stokes M.G., Titball R.W., Neeson B.N., Galen J.E., Walker N.J., Stagg A.J., et al. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis. Infect Immun 2007, 75:1827-1834.
61. Macpherson A.J., McCoy K.D., Johansen F.E., Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol 2008, 1:11-22.
62. Kong Q., Richter L., Yang Y.F., Arntzen C.J., Mason H.S., Thanavala Y. Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc Natl Acad Sci USA 2001, 98:1539-1544.
63. Zhang X., Buehner N.A., Hutson A.M., Estes M.K., Mason H.S. Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein. Plant Biotechnol J 2006, 4:419-432.
64. Chikwamba R., Cunnick J., Hathaway D., McMurray J., Mason H., Wang K. A functional antigen in a practical crop: LT-B producing maize protects mice against Escherichia coli heat labile enterotoxin (LT) and cholera toxin (CT). Transgenic Res 2002, 11:479-493.
65. Mosmann T.R., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996, 17:138-146.
66. Cox J.C., Coulter A.R. Adjuvants - a classification and review of their modes of action. Vaccine 1997, 15:248-256.
67. Lindblad E.B. Aluminium adjuvants - in retrospect and prospect. Vaccine 2004, 22:3658-3668.
68. Marinaro M., Boyaka P.N., Jackson R.J., Finkelman F.D., Kiyono H., Jirillo E., et al. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin. J Immunol 1999, 162:114-121.
69. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11:S45-S53.
70. Rontani C.M., Levy W., Labruyere, Mock M. Germination of Bacillus anthracis spores within alveolar macrophages. Mol Microbiol 1999, 31:9-17.
71. Welkos S., Friedlander A., Weeks S., Little S., Mendelson I. In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. J Med Microbiol 2002, 51:821-831.
72. Reuveny S., White M.D., Adar Y.Y., Kafri Y., Altboum Z., Gozes Y., et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 2001, 69:2888-2893.
73. Marcus H., Danieli R., Epstein E., Velan B., Shafferman A., Reuveny S. Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine. Infect Immun 2004, 72:3471-3477.
74. Dufourmantel N., Pelissier B., Garcon F., Peltier G., Ferullo J.M., Tissot G. Generation of fertile transplastomic soybean. Plant Mol Biol 2004, 55:479-489.
75. Kumar S., Dhingra A., Daniell H. Plastid-expressed betaine aldehyde dehydrogenase gene in carrot cultured cells, roots, and leaves confers enhanced salt tolerance. Plant Physiol 2004, 136:2843-2854.
76. Kanamoto H, Yamashita A., Asao H., Okumura S., Takase H., Hattori M., et al. Efficient and stable transformation of Lactuca sativa L. cv. Cisco (lettuce) plastids. Transgenic Res 2006, 15:205-217.